GYRE Earnings Date: Nov 6, 2026 (Estimated) — Gyre Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology
Updated
When is GYRE's next earnings date?
Gyre Therapeutics, Inc. (GYRE) is expected to report Q3 2026 earnings on Friday, November 6, 2026 at 6:00 AM ET (before market open); the date is an estimate and has not been confirmed by the company. The consensus estimate is EPS of -$0.15 on revenue of $28.4M.
How did GYRE do in its last earnings report?
In its most recent report on Aug 7, 2026 (Q2 2026), Gyre Therapeutics, Inc. posted EPS of -$0.12 versus the -$0.06 estimate, a miss of 100.0%. Revenue was $29.1M against a $26.5M estimate. The stock's 1-day post-earnings move was +4.2%.
How much does GYRE stock move after earnings?
GYRE beat EPS estimates in 3 of its last 5 reported quarters. Over the last 8 reports the stock moved an average of 9.2% (up or down) in the day after earnings.
About Gyre Therapeutics, Inc.
Gyre Therapeutics, Inc. is a pharmaceutical company dedicated to discovering, advancing, and bringing to market small-molecule drugs that target inflammation and fibrosis in various organs. The company's key anti-fibrotic medication, ETUARY (Pirfenidone), has received approval for treating idiopathic pulmonary fibrosis. Beyond this, ETUARY is also undergoing late-stage (Phase 3) clinical trials for several other conditions, including dermatomyositis and interstitial lung disease linked to systemic sclerosis, pneumoconiosis, and diabetic kidney disease. The company's pipeline further includes F351 (Hydronidone), a compound structurally related to ETUARY. F351 is currently in Phase 3 studies for chronic hepatitis B-induced liver fibrosis and is in Phase 1 trials for liver fibrosis associated with nonalcoholic associated steatohepatitis (NASH). Other programs in development feature F573, which is progressing through Phase 2 studies for acute and acute-on-chronic liver failure. Additionally, two early-stage candidates, F528 and F230, are in preclinical development, focusing on chronic obstructive pulmonary disease (COPD) and pulmonary arterial hypertension (PAH), respectively. Established in 2002, Gyre Therapeutics, Inc. is based in San Diego, California, and operates as a subsidiary of GNI USA, Inc.
Earnings History
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-08-07 | Q2 2026 | -0.06 | -0.12 | -100.00% | $29.1M | ❌ Miss | +4.22% | +2.19% | +7.19% |
| 2026-05-07 | Q1 2026 | -0.07 | -0.04 | +35.71% | $22.5M | ✅ Beat | -12.06% | -9.45% | -21.77% |
| 2026-03-12 | Q4 2025 | 0.04 | 0.05 | +15.00% | $37.2M | ✅ Beat | -6.30% | -15.85% | -11.28% |
| 2025-11-07 | Q3 2025 | 0.01 | 0.03 | +200.00% | $30.6M | ✅ Beat | -1.77% | +10.08% | +11.17% |
| 2025-08-11 | Q2 2025 | 0.03 | 0.00 | -100.00% | $26.8M | ❌ Miss | +6.93% | +11.03% | +15.56% |
| 2025-03-17 | Q4 2024 | — | 0.00 | — | $27.9M | — | -30.21% | -25.00% | -31.60% |
| 2024-11-13 | Q3 2024 | — | 0.01 | — | $25.5M | — | -9.56% | -19.30% | -38.91% |
| 2024-08-13 | Q2 2024 | — | 0.01 | — | $25.2M | — | -2.53% | +10.22% | +29.24% |
Showing last 8 quarters.